Binnopharm  to acquire Anti-bacterial Brands from Dr Reddy's

Sistema Group company Binnopharm Group will sell the anti-bacterial medicines of Dr. Reddy’s laboratories under the Ciprolet and Levolet brands in Russia. Both the companies said in a joint statement that they would acquire Reddy's Laboratories under the Ciprolet and Revolet brands in Russia, Uzbekistan and Belarus.

Binnopharm Group, one of the leading Russian pharmaceutical companies, has concluded a contract with Dr. Reddy's. The product portfolio includes various dosage forms such as tablets,  infusions, and eye drops. However, the company did not reveal financial details.

Binnopharm Group CEO Rustem Muratov has said that the acquisition of Ciprolet and Levolet is important for the enhancement of their position in the antibiotics market, which is also one of the key market segments of the Binnopharm Group. These brands already had the trust of millions of consumers, which only serves positively for the acquisition.

He further said that the products will complement the company’s portfolio of antibacterial products. The company is also acquiring the rights to these products in Belarus and Uzbekistan in line with its strategic goal to strengthen its presence in the international markets. During the transition period, Dr. Reddy's will continue to supply products to the Binnopharm Group to ensure market availability.